Serum Glucagon like peptide 1 Level and Peripheral Vascular Disease in Patients with Type 2 Diabetes
Abstract Background Diabetes is a complex, chronic illness requiring continuous medical care with multifactorial risk-reduction strategies beyond glycemic control. Incretins are hormones produced by the intestinal mucosa in response to oral intake of nutrients that enhance glucose-stimulated insulin...
Gespeichert in:
| Veröffentlicht in: | QJM : An International Journal of Medicine 2021-10, Vol.114 (Supplement_1) |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | Supplement_1 |
| container_start_page | |
| container_title | QJM : An International Journal of Medicine |
| container_volume | 114 |
| creator | El Baki, Rania Sayed Abd Sami Nasr, Merhan Mostafa, Bassem Murad Ibrahim, Ahmed Abe Bakr El Sayed |
| description | Abstract
Background
Diabetes is a complex, chronic illness requiring continuous medical care with multifactorial risk-reduction strategies beyond glycemic control. Incretins are hormones produced by the intestinal mucosa in response to oral intake of nutrients that enhance glucose-stimulated insulin secretion and lower blood glucose levels. GLP-1 is of particular interest for its glucoselowering effects, as well as its ability to slow gastric emptying and suppress secretion of glucagon.
Objective
To assess the level of glucagon like peptide-1 in type 2 diabetic patients with peripheral vascular disease.
Patients and Methods
Our study was conducted in the period from 1st of January to 1st of June 2017. Our subjects were collected from the diabetes clinics of Ain Shams university Hospitals. The study included eighty (80) patients divided into 40 type 2 diabetic patients without peripheral vascular disease (Group 1) and 40 type 2 diabetic patients with peripheral vascular disease (Group 2).
Results
Diabetic patients with peripheral vascular disease show statistically significant higher HbA1c levels than diabetic patients without peripheral vascular disease with P-value 0.005 (P-value |
| doi_str_mv | 10.1093/qjmed/hcab100.009 |
| format | Article |
| fullrecord | <record><control><sourceid>oup_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1093_qjmed_hcab100_009</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/qjmed/hcab100.009</oup_id><sourcerecordid>10.1093/qjmed/hcab100.009</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1229-53315ee7eeafa86a78a96115d83c761c8505271669ac58bd90cc16092d73460c3</originalsourceid><addsrcrecordid>eNqNkN1OAjEQRhujiYg-gHd9ABf6Q9vtpUFFExJJRG83QztIcVnWdlfC27sK3nv1TfLNmWQOIdecDTizcvi53qAfrhwsOGMDxuwJ6fGRZpmQVp7-zUaoc3KR0poxNjKjvEf8C8Z2Qydl6-B9W9EyfCCtsW6CR8rpFL-wpFB5OsMY6hVGKOkbJNeWEOldSAgJaajoDJqAVZPoLjQrOt_XSEXXwwIbTJfkbAllwqtj9snrw_18_JhNnydP49tp5rgQNlNScoVoEGEJuQaTg9WcK59LZzR3uWJKGK61BafyhbfMOa6ZFd7I7j0n-4Qf7rq4TSnisqhj2EDcF5wVP5qKX03FUVPRaeqYmwOzbet_rH8Dk_hrcg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Serum Glucagon like peptide 1 Level and Peripheral Vascular Disease in Patients with Type 2 Diabetes</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>El Baki, Rania Sayed Abd ; Sami Nasr, Merhan ; Mostafa, Bassem Murad ; Ibrahim, Ahmed Abe Bakr El Sayed</creator><creatorcontrib>El Baki, Rania Sayed Abd ; Sami Nasr, Merhan ; Mostafa, Bassem Murad ; Ibrahim, Ahmed Abe Bakr El Sayed</creatorcontrib><description>Abstract
Background
Diabetes is a complex, chronic illness requiring continuous medical care with multifactorial risk-reduction strategies beyond glycemic control. Incretins are hormones produced by the intestinal mucosa in response to oral intake of nutrients that enhance glucose-stimulated insulin secretion and lower blood glucose levels. GLP-1 is of particular interest for its glucoselowering effects, as well as its ability to slow gastric emptying and suppress secretion of glucagon.
Objective
To assess the level of glucagon like peptide-1 in type 2 diabetic patients with peripheral vascular disease.
Patients and Methods
Our study was conducted in the period from 1st of January to 1st of June 2017. Our subjects were collected from the diabetes clinics of Ain Shams university Hospitals. The study included eighty (80) patients divided into 40 type 2 diabetic patients without peripheral vascular disease (Group 1) and 40 type 2 diabetic patients with peripheral vascular disease (Group 2).
Results
Diabetic patients with peripheral vascular disease show statistically significant higher HbA1c levels than diabetic patients without peripheral vascular disease with P-value 0.005 (P-value <0.05). GLP 1 was highly significantly positively correlated with APSV with P-value< 0.001. GLP 1 correlated negatively with BMI, FBS, 2h PPBS and HbA1C; with statistically significant difference; P-value (0.031, 0.015, 0.033 and 0.010 respectively) but was not significantly negatively correlated with age, SBP and DBP; P-value (0.232, 0.654 and 0.335 respectively).
Conclusion
GLP-1 levels are lower in diabetic patients with peripheral vascular disease than diabetic patients without peripheral vascular disease. GLP-1 levels showed significantly lower levels with increasing degree of obesity, FBS, PPBS and HbA1c.</description><identifier>ISSN: 1460-2725</identifier><identifier>EISSN: 1460-2393</identifier><identifier>DOI: 10.1093/qjmed/hcab100.009</identifier><language>eng</language><publisher>Oxford University Press</publisher><ispartof>QJM : An International Journal of Medicine, 2021-10, Vol.114 (Supplement_1)</ispartof><rights>The Author(s) 2021. Published by Oxford University Press on behalf of the Association of Physicians. All rights reserved. For permissions, please email: journals.permissions@oup.com 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids></links><search><creatorcontrib>El Baki, Rania Sayed Abd</creatorcontrib><creatorcontrib>Sami Nasr, Merhan</creatorcontrib><creatorcontrib>Mostafa, Bassem Murad</creatorcontrib><creatorcontrib>Ibrahim, Ahmed Abe Bakr El Sayed</creatorcontrib><title>Serum Glucagon like peptide 1 Level and Peripheral Vascular Disease in Patients with Type 2 Diabetes</title><title>QJM : An International Journal of Medicine</title><description>Abstract
Background
Diabetes is a complex, chronic illness requiring continuous medical care with multifactorial risk-reduction strategies beyond glycemic control. Incretins are hormones produced by the intestinal mucosa in response to oral intake of nutrients that enhance glucose-stimulated insulin secretion and lower blood glucose levels. GLP-1 is of particular interest for its glucoselowering effects, as well as its ability to slow gastric emptying and suppress secretion of glucagon.
Objective
To assess the level of glucagon like peptide-1 in type 2 diabetic patients with peripheral vascular disease.
Patients and Methods
Our study was conducted in the period from 1st of January to 1st of June 2017. Our subjects were collected from the diabetes clinics of Ain Shams university Hospitals. The study included eighty (80) patients divided into 40 type 2 diabetic patients without peripheral vascular disease (Group 1) and 40 type 2 diabetic patients with peripheral vascular disease (Group 2).
Results
Diabetic patients with peripheral vascular disease show statistically significant higher HbA1c levels than diabetic patients without peripheral vascular disease with P-value 0.005 (P-value <0.05). GLP 1 was highly significantly positively correlated with APSV with P-value< 0.001. GLP 1 correlated negatively with BMI, FBS, 2h PPBS and HbA1C; with statistically significant difference; P-value (0.031, 0.015, 0.033 and 0.010 respectively) but was not significantly negatively correlated with age, SBP and DBP; P-value (0.232, 0.654 and 0.335 respectively).
Conclusion
GLP-1 levels are lower in diabetic patients with peripheral vascular disease than diabetic patients without peripheral vascular disease. GLP-1 levels showed significantly lower levels with increasing degree of obesity, FBS, PPBS and HbA1c.</description><issn>1460-2725</issn><issn>1460-2393</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNqNkN1OAjEQRhujiYg-gHd9ABf6Q9vtpUFFExJJRG83QztIcVnWdlfC27sK3nv1TfLNmWQOIdecDTizcvi53qAfrhwsOGMDxuwJ6fGRZpmQVp7-zUaoc3KR0poxNjKjvEf8C8Z2Qydl6-B9W9EyfCCtsW6CR8rpFL-wpFB5OsMY6hVGKOkbJNeWEOldSAgJaajoDJqAVZPoLjQrOt_XSEXXwwIbTJfkbAllwqtj9snrw_18_JhNnydP49tp5rgQNlNScoVoEGEJuQaTg9WcK59LZzR3uWJKGK61BafyhbfMOa6ZFd7I7j0n-4Qf7rq4TSnisqhj2EDcF5wVP5qKX03FUVPRaeqYmwOzbet_rH8Dk_hrcg</recordid><startdate>20211001</startdate><enddate>20211001</enddate><creator>El Baki, Rania Sayed Abd</creator><creator>Sami Nasr, Merhan</creator><creator>Mostafa, Bassem Murad</creator><creator>Ibrahim, Ahmed Abe Bakr El Sayed</creator><general>Oxford University Press</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20211001</creationdate><title>Serum Glucagon like peptide 1 Level and Peripheral Vascular Disease in Patients with Type 2 Diabetes</title><author>El Baki, Rania Sayed Abd ; Sami Nasr, Merhan ; Mostafa, Bassem Murad ; Ibrahim, Ahmed Abe Bakr El Sayed</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1229-53315ee7eeafa86a78a96115d83c761c8505271669ac58bd90cc16092d73460c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>El Baki, Rania Sayed Abd</creatorcontrib><creatorcontrib>Sami Nasr, Merhan</creatorcontrib><creatorcontrib>Mostafa, Bassem Murad</creatorcontrib><creatorcontrib>Ibrahim, Ahmed Abe Bakr El Sayed</creatorcontrib><collection>CrossRef</collection><jtitle>QJM : An International Journal of Medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>El Baki, Rania Sayed Abd</au><au>Sami Nasr, Merhan</au><au>Mostafa, Bassem Murad</au><au>Ibrahim, Ahmed Abe Bakr El Sayed</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Serum Glucagon like peptide 1 Level and Peripheral Vascular Disease in Patients with Type 2 Diabetes</atitle><jtitle>QJM : An International Journal of Medicine</jtitle><date>2021-10-01</date><risdate>2021</risdate><volume>114</volume><issue>Supplement_1</issue><issn>1460-2725</issn><eissn>1460-2393</eissn><abstract>Abstract
Background
Diabetes is a complex, chronic illness requiring continuous medical care with multifactorial risk-reduction strategies beyond glycemic control. Incretins are hormones produced by the intestinal mucosa in response to oral intake of nutrients that enhance glucose-stimulated insulin secretion and lower blood glucose levels. GLP-1 is of particular interest for its glucoselowering effects, as well as its ability to slow gastric emptying and suppress secretion of glucagon.
Objective
To assess the level of glucagon like peptide-1 in type 2 diabetic patients with peripheral vascular disease.
Patients and Methods
Our study was conducted in the period from 1st of January to 1st of June 2017. Our subjects were collected from the diabetes clinics of Ain Shams university Hospitals. The study included eighty (80) patients divided into 40 type 2 diabetic patients without peripheral vascular disease (Group 1) and 40 type 2 diabetic patients with peripheral vascular disease (Group 2).
Results
Diabetic patients with peripheral vascular disease show statistically significant higher HbA1c levels than diabetic patients without peripheral vascular disease with P-value 0.005 (P-value <0.05). GLP 1 was highly significantly positively correlated with APSV with P-value< 0.001. GLP 1 correlated negatively with BMI, FBS, 2h PPBS and HbA1C; with statistically significant difference; P-value (0.031, 0.015, 0.033 and 0.010 respectively) but was not significantly negatively correlated with age, SBP and DBP; P-value (0.232, 0.654 and 0.335 respectively).
Conclusion
GLP-1 levels are lower in diabetic patients with peripheral vascular disease than diabetic patients without peripheral vascular disease. GLP-1 levels showed significantly lower levels with increasing degree of obesity, FBS, PPBS and HbA1c.</abstract><pub>Oxford University Press</pub><doi>10.1093/qjmed/hcab100.009</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1460-2725 |
| ispartof | QJM : An International Journal of Medicine, 2021-10, Vol.114 (Supplement_1) |
| issn | 1460-2725 1460-2393 |
| language | eng |
| recordid | cdi_crossref_primary_10_1093_qjmed_hcab100_009 |
| source | Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| title | Serum Glucagon like peptide 1 Level and Peripheral Vascular Disease in Patients with Type 2 Diabetes |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T16%3A33%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-oup_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Serum%20Glucagon%20like%20peptide%201%20Level%20and%20Peripheral%20Vascular%20Disease%20in%20Patients%20with%20Type%202%20Diabetes&rft.jtitle=QJM%20:%20An%20International%20Journal%20of%20Medicine&rft.au=El%20Baki,%20Rania%20Sayed%20Abd&rft.date=2021-10-01&rft.volume=114&rft.issue=Supplement_1&rft.issn=1460-2725&rft.eissn=1460-2393&rft_id=info:doi/10.1093/qjmed/hcab100.009&rft_dat=%3Coup_cross%3E10.1093/qjmed/hcab100.009%3C/oup_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_oup_id=10.1093/qjmed/hcab100.009&rfr_iscdi=true |